Alphatec Q4 results expected to beat consensus at Summer Street Summer Street expects Alphatec (ATEC) to report Q4 results above consensus estimates and keeps a Buy rating on the stock with a $5 price target. The firm believes the company will benefit from an improving spine market, which it notes was evident in Globus Medical's (GMED) results.
News For ATEC;GMED From The Last 14 Days
Check below for free stories on ATEC;GMED the last two weeks.
Globus Medical downgraded to Hold from Buy at WallachBeth WallachBeth downgraded Globus Medical citing valuation but raised its price target for shares to $27 from $23 following the company's Q4 results.